mRNA vaccine for older adults to prevent RSV and hMPV
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new mRNA vaccine designed to protect older adults against two common respiratory viruses, RSV and hMPV. It aims to see if the vaccine is safe and creates a good immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are in good general health, or have stable chronic conditions that are under control.
- You are at least 18 years old, but this study is for healthy older adults (likely 60 or older – ask the study team).
- Your weight is in a healthy range for your height (body mass index between 18.5 and 35).
- You have never had a severe allergic reaction (anaphylaxis) to any mRNA vaccine or its ingredients.
- You have not received an RSV vaccine before, and you have not been in a study with RSV or hMPV vaccines.
- You do not have a weak immune system, an autoimmune disease, or a history of certain blood or organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This study tests a new vaccine designed to protect against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. The vaccine is given as a shot, and the study will check how your immune system responds to it.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.